Obsidian Therapeutics has appointed Paul Wotton to serve as its new CEO. Wotton succeeds CEO Michael Gilman, who had been splitting his time between Obsidian and Arrakis Therapeutics. Gilman is now CEO of Arrakis full-time. Wotton is the former president and CEO of Sigilon Therapeutics. Cambridge, MA-based Obsidian is developing cell and gene therapies incorporating technologies intended to these treatments more controllable.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
